Skip to main content

Table 2 Lupus and scleroderma disease presentation according to autoantibody serology, manifestations and tests

From: DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis

Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SSc)
(n = 30) (n = 30)
Autoantibodies, manifestations and tests SLEDAI score Autoantibodies and manifestations dcSSC(n = 14) lcSSc(n = 5) “other” (e.g. UCTD, morphea, Reynaud’s) (n = 3) Unclassified(n = 7)
Mild, score <10(n = 21) Moderate, score 10–20 (n = 3) Severe, score >20 (n =0) unscored (n = 6) ANA positive (n = 22) 73 % 13 6 5 n/a
ANA positive (n = 29) 97 % 20 3 0 6 ACA positive (n = 6) 20 % 3 2 1 n/a
DLE positive (n = 19) 63 % 15 2 0 3 ATA positive (n = 2) 7 % 2 0 0 n/a
Coombs’ test positive (n = 14) 47 % 9 3 0 3 ILD (n = 10) 33 % 6 1 3 n/a
  1. Abbreviations: ACA, anticentromere autoantibody; ANA, anti-nuclear antibodies; ATA, Antitopoisomerase antibodies; Coombs’ test, detects presence of antibodies that act against the surface of red blood cells, indicates haemolytic anaemia; DLE, Discoid lupus erythematosus; ILD, interstitial lung disease, indicator of direct pulmonary involvement, and leading cause of death; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; UCTD, undifferentiated connective tissue disease; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; n/a, results not available.